Adherium Raises USD 1.65 Million via Short-Term Unsecured Loan

Loan Facility Details and Terms

Adherium Limited (ASX:ADR) has secured a USD 1.65 million short-term loan facility from Trudell Medical Limited, its major shareholder and a global player in aerosol drug delivery. The unsecured loan carries a 12% per annum interest rate, with interest capitalised monthly until repayment. The repayment date is set for 30 September 2026 but can be extended on a month-to-month basis by mutual agreement. Early repayment is permitted without penalty, and the loan becomes immediately repayable upon any event of default.

Strategic Rationale Behind Shareholder Loan

The Adherium board opted for this shareholder loan over third-party financing due to limited and uncertain external funding options, which would likely come on less favourable terms. The loan avoids diluting existing shareholders and offers quick access to capital, crucial for meeting immediate working capital requirements. This bridge funding comes as Adherium pursues a 1-for-100 share consolidation approved by shareholders earlier this month, aiming to streamline its capital structure and bolster its financial position while exploring R&D lending opportunities.

Governance and Board Considerations

In assessing the loan facility, the board, excluding Mr George Baran, who is associated with Trudell, determined that the terms were negotiated at arm’s length and comparable to similar short-term loans with unrelated parties. Consequently, the loan does not require shareholder approval under the Corporations Act 2001. This internal funding move reflects the company’s current financing environment and its efforts to maintain operational liquidity without immediate equity dilution.

Positioning Amid Capital Structure Changes

This facility provides a financial bridge while Adherium implements its recent share consolidation, which was designed to reduce the number of shares on issue and improve marketability. The consolidation, approved at the June 2026 extraordinary general meeting, is part of a broader strategy to enhance the company’s capital structure and support growth initiatives. Meanwhile, the company continues to explore R&D lending options that may offer more appropriate long-term funding solutions.